NGS HRD Gene Panel

HRD mutations has role as Prognostic and Predictive biomarker. HRD is associated with an increased sensitivity to platinum-based chemotherapy and PARP inhibitors. Results from the homologous recombination repair deficiency test can provide valuable information for personalized cancer treatment, such as identifying patients who may benefit from PARP inhibitor therapy. 

Who should be tested?

Any woman diagnosed with epithelial ovarian, fallopian tube, and peritoneal cancers can undergo genetic testing as per SGO recommendation, or women with ovarian cancer who may benefit from PARPi maintenance therapy, or women with ovarian cancer resistant to platinum therapy.

Note: Genetic counseling can be provided. If interested, please send the request to this email id: [email protected]

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.